Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, Number of Procedue Conducted & ASP by Technology & Application The global neuromodulation devices market will witness a robust CAGR of 10.28%, valued at $6.09 billion in 2021, expected to appreciate and reach $14.17 billion by 2030, confirms Strategic Market Research. North America had the largest share globally, with a value of over 60% in 2021. Neuromodulation is a natural alteration of synaptic and neuronal properties of a neuron by the neuron itself, while neurostimulation is a forced modulation of a person’s nervous system using invasive or non-invasive procedures. The neuromodulation device consists of a pulse generator and two electrodes applied to the brain, spinal cord, or peripheral nerves. A pulse is supplied from the generator to the contact area, modulating the nerve. The earliest record of neuromodulation was in 46th AD when Scribonius Largus used torpedo fish as a treatment to relieve headaches. The modern neuromodulation era began in the 1960s, first with deep brain stimulation, followed by spinal cord stimulation in 1967. Neuromodulation can be considered as an alternative to long-term drug therapy for the symptomatic relief of chronic or persistent conditions, which occurs when the drugs are ineffective or problematic to the patient. Neuromodulation devices stimulate the nerves with electrical signals, pharmaceutical agents, and other forms of energy by effectively modulating the abnormal neural pathway behavior that is caused by the disease process. Since they are tailored, Neuromodulation therapies can avoid the adverse effects of more systemic or irreversible treatments of nervous system disorders. They can also give patients and clinicians a basic level of therapeutic control since they are easily reversible. Neuromodulation and neurostimulation devices are being implanted more frequently to normalize nervous system actions and alleviate symptoms of neurological conditions. According to an NCBI study, around 50,000 spinal cord neurostimulators are implemented annually to treat patients with severe and chronic pain due to various conditions, such as failed back surgery/arachnoiditis, neuropathy, and other neurological disorders. Spinal cord stimulators have been used increasingly recently, with a long-term success rate of up to 74%. Key Industry Drivers - Increasing Number of Clinical Applications, Growing Prevalence of Neurological, Respiratory, and Other Conditions The constant focus of major industry leaders on R&D investment for the establishment of clinical effectiveness and expansion of the clinical applications of these devices is one major factor that positively shifts the neuromodulation market trends. For example, neuromodulation devices can be used to treat tinnitus. A non-invasive method using a repetitive transcranial magnetic stimulator helps minimize tinnitus by sending an intermittent magnetic field through the brain. Tinnitus is a genetic disease, and according to the CDC, nearly 15% of the American general public – about 50 million people experience some form of tinnitus, while according to the Office for National Statistics, around 7.1 million British citizens aged 17-99 suffer from tinnitus. The world is currently seeing a growing frequency of neurological, respiratory, and other conditions. According to the WHO, 40-50 million patients have epilepsy worldwide, while according to Johns Hopkins Medicine, spasticity affects around 12 million people worldwide. As stated by Cystic Fibrosis Foundation, more than 30,000 individuals live with cystic fibrosis in America, while more than 70,000 people suffer from this disease worldwide. The global neuromodulation devices market is growing with the rising prevalence of neurological, respiratory, and other conditions. Restraints - Lower Diagnosis and Treatment Rates in Developing Countries Neurological conditions like epilepsy, depression, and others are growing in developing countries like India, Brazil, and China. According to the WHO, 54 million people suffer from depression in China. However, the lower diagnosis and treatment rates mean fewer people have access to neuromodulation devices, hindering the market growth. Opportunities - Technological Advancements The increasing number of devices available for neuromodulation and neurostimulation can help boost industry growth. Devices like an electrical stimulator, functional electrical stimulator, percutaneous tibial nerve stimulator, peripheral nerve stimulator, transcranial direct current stimulator, and transcutaneous electrical nerve stimulator, using phenomena such as transcranial pulsed electromagnetic fields will have increased applications, boosting the market growth. Using transcranial pulsed electromagnetic fields is a promising method to treat resistant depression. According to a study, 30% of people with diagnosed depression have resistant depression. Neuromodulation devices have already received FDA approval in the United States for treating epilepsy, depression, movement disorders, & other serious Neurological illnesses. It is presumed that by the end of the year 2035, significant advancements in the field of neuroanatomical networks integrated with substantial developments in miniaturization, material science, & energy storage will cater to a plethora of opportunities for market growth. Recently, the WHO has reported that close to 50 million people worldwide suffering from epilepsy reside in middle and low-income countries. Further, it has been figured out that nearly 70% of people having epilepsy can live seizure-free if they are adequately diagnosed & treated. Market Analysis Of Different Segments Covered in the Report Based on Product Sacral Nerve Stimulator Deep Brain Stimulator Gastric Electric Stimulator Vagus Nerve Stimulator Spinal Cord Stimulator Based on Application Dystonia Depression Essential Tremor Urinary and Fecal Incontinence Epilepsy Pain Management Gastroparesis Parkinson’s Disease Other Regional Coverage Analysis North America United States Canada Mexico Rest of North America Europe Germany France Sweden Netherlands Switzerland Austria Belgium Denmark Ireland Finland United Kingdom Italy Rest of Europe Asia-Pacific China Japan India South Korea Singapore Australia Rest of Asia-Pacific LAMEA Brazil Argentina Chile Bahrain Egypt Iran Iraq Israel Kuwait Oman Qatar Saudi Arabia United Arab Emirates Turkey Rest of LAMEA Segments Analysis & Insights The spinal cord stimulator segment spearheaded the industry in 2021, accounting for more than 51.5%. Due to the huge scope of product application, increasing spinal cord disorders, and increased market penetration of commercially available products, this segment’s neuromodulation devices market share has grown. 250,000 people suffer from spinal cord injuries, according to the National Spinal Cord Injury Association. However, the sacral nerve stimulator segment is expected to be the fastest-growing market, with a CAGR of 13.7%. Increasing awareness regarding sacral neuromodulation and the rising number of urological issues is the major driving factor for the segment’s growth. According to an IDPH (Illinois Department of Public Health) study, 13 million adults have urinary incontinence, while according to the NIH, around 1 in 10 men over the age of 70 can develop urinary retention. The pain management segment had the highest industry size, with over 68% in 2021. The high occurrence of chronic pain disorders (such as arthritis) and increased usage of products for pain management due to their high and increased therapeutic value are expected to drive this segment’s growth. According to the CDC, around 23.7% of the US population, or 58.5 million people, have doctor-diagnosed arthritis. North America held the largest market segment, with more than 60% in 2021. Increased availability of neuromodulation devices, a rising number of diseases (such as migraine), more neuromodulation device manufacturers in the US, and skilled medical professionals resulted in North America’s dominance in the industry. A study by the NCBI shows that there are 26 million migraine patients in the US alone. However, Asia-Pacific will be the fastest-growing market, with a CAGR of 21.3%. Due to the shift of international manufacturers to this region because of untapped growth opportunities and unmet medical needs, the market growth in this region is expected to be rapid. According to a study, over 56 million Indians suffer from depression and require medical intervention. Neuromodulation Devices Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 6.09 billion The revenue forecast in 2030 USD 14.71 billion Growth rate CAGR of approximately 10.28% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Application, and By Region By Type Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Spinal Cord Stimulator, Gastric Electric Stimulator By Application Pain Management, Essential Tremor, Urinary, and Faecal Incontinence, Dystonia, Gastroparesis, Epilepsy Parkinson’s Disease, Depression, Other By Region Asia Pacific, North America, Europe, LAMEA Country Scope United States of America, Australia, United Kingdom, Germany, France, Italy, Spain, Russia, Canada, China, Japan, India, South Korea, Singapore, Brazil, Mexico, Argentina, Saudi Arabia, United Arab Emirates, South Africa Company Usability Profiles Medtronic, Boston Scientific Corporation, Abbott Laboratories, LivaNova, Synapse Biomedical, Nevro Corporation, NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Inc., BioControl Medical, Bioness, Soterix Medical, Integer Holdings Corporation, Bioinduction, GiMer Medical, GTX Medical, Helius Medical Technologies, MicroTransponder, Neuronano, BlueWind Neuromodulation Devices Market Competitive Landscape Analysis The key industry leaders focus more on R&D activities for developing novel technologies and products. Mergers & Acquisitions and regional expansions are strategies that the companies adopt to gain and maintain their competitive advantage. The major leaders in the global industry are: Medtronic Boston Scientific Corporation Abbott Laboratories LivaNova Synapse Biomedical Nevro Corporation NeuroSigma, Inc. NeuroPace, Inc. Neuronetics, Inc. BioControl Medical Bioness Soterix Medical Integer Holdings Corporation Bioinduction GiMer Medical GTX Medical Helius Medical Technologies MicroTransponder Neuronano BlueWind The Abbott market share is 16.7%, which currently is the highest share by a company in the industry. Recent Developments On July 2022, CVRx launched a brand new Barostim Programmer, the first FDA-approved neuromodulation device in the world, to treat the various symptoms of cardiac failure. This 2nd generation Barostim programmer has a highly modernized design & it operates on a highly upgraded cellular network that provides 360-degree access on remote view. It also inculcates a highly advanced user interface that helps to simplify the IPG programming. On July 2022, Orchestra BioMed collaborated with Medtronic for the purpose of heart neuromodulation therapy. This collaboration with Medtronic will stimulate the overall progress of its development of BackBeat CNT (Cardiac Neuromodulation Therapy), a highly upgraded level of treatment for patients suffering from hypertension, and indicate the requirement for a pacemaker. On June 2022, SpineX enrolled its 1st patient for Scone Therapy, a highly upgraded trial therapy for spinal neuromodulation. Through this Scone Neuromodulation device, Spine X would evaluate the level of efficacy and safety of this technology for neurogenic bladder treatment in the future. Moreover, this therapy can potentially treat some serious symptoms like lower bladder capacity, a sensation of bladder fullness, & urine leakage. In April 2022, Greenbook TMS, Inc. and Neuronetics, Inc. announced a five-year commercial agreement for stronger collaboration. Greenbrook will exclusively purchase its devices for on-label indications from Neuronetics. At the same time, Neuronetics will provide joint education and marketing support, negotiated price terms, increased collaboration between the companies, and other benefits. The partnership is expected to build category awareness, educate MDD patients and their families and friends, raise the neuro health care standards and transform lives. In February 2022, NeuroSigma, Inc. announced the FDA Breakthrough Device Designation for its Monarch eTNS System for adjunctive use to reduce the frequency of seizures in epileptic patients 18 years or older. Through this designation, NeroSigma believes that it could provide earlier access to novel technologies for these patients, which could help them recover from their condition. In February 2022, LivaNova announced the first patient implanted in their OSPREY clinical study. The randomized clinical trial aims to demonstrate the effectiveness and safety of the LivaNova aura6000 System, an implantable hypoglossal neurostimulator aiming to treat patients with moderate to severe obstructive sleep apnea (OSA). LivaNova believes that through this study, they would be taking a major step towards finding effective and new treatments for global obstructive sleep apnea patients. In January 2022, Nevro Corporation announced UnitedHealthcare Coverage for its high-frequency 10 kHz neuromodulation therapy to treat painful diabetic neuropathy (PDN). The coverage decision from UnitedHealthcare will help more PDN patients access its high-frequency 10 kHz therapy. In November 2021, NeuroPace, Inc. announced an investigational device exemption (IDE) from the FDA to study its RNS system in drug-resistant idiopathic generalized epilepsy (IGE) patients. The pivotal study, termed NAUTILUS, will be the first to evaluate the use of brain-responsive neuromodulation for IGE treatment. NeuroPace believes that the study will help the organization find new treatment procedures to potentially improve the quality of life for IGE patients in a meaningful way. Various Devices that Key Market Leaders Develop: Product Function Key Player Synchromed II Intrathecal Pump Treatment of severe spasticity. Medtronic Infinity DBS system Symptom control for patients with Parkinson’s disease and essential tremors. Abbott Laboratories O-Armilla Pain relief for patients with Carpal tunnel syndrome. GiMer Medical aura6000 system Treatment of obstructive sleep apnea. LivaNova WaveWriter Alpha Spinal Cord Stimulator Providing the patient with long-lasting and personalized pain relief. Boston Scientific Corporation Frequently Asked Question About This Report What is the growth rate during the forecast period? The growth rate of the neuromodulation market during the forecast period is 10.28%. What are the market values/growth % of emerging countries? The market growth in emerging countries is 21.3%. How big is the neuromodulation devices market? The global neuromodulation devices market size was $5.53 billion in 2020 and is predicted to reach $6.72 billion in 2022. What is a neuromodulation device? A neuromodulation device is an instrument that sends out electromagnetic pulses to modulate the nerve naturally. What are the key market trends in the global neurostimulation devices market report? The increasing number of clinical applications and the growing prevalence of neurological, respiratory, and other conditions are the key trends in the global neurostimulation devices market. Who is the leader in neuromodulation? Abbott Laboratories is the current leader in neuromodulation. What are some examples of neuromodulation? Spinal cord stimulation, deep brain stimulation, sacral neuromodulation, vagus nerve stimulation, and gastric electric stimulation are some examples. Sources https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391880/ https://www.cdc.gov/nceh/hearing_loss/public_health_scientific_info.html https://minervahearing.co.uk/.well-known/captcha/?r=%2Fblog%2Ftinnitus%2F https://www.hopkinsmedicine.org/health/conditions-and-diseases/spasticity 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Neuromodulation Devices Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Neuromodulation Devices Market 4.2.1 Market, 2021 - 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021 - 2030 (USD Million) 4.4 Product Business Analysis 4.4.1 Market, By Product, 2021 - 2030 (USD Million) 4.5 Application Business Analysis 4.5.1 Market, By Application, 2021 - 2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 Market PEST analysis 4.8.2 Market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2021) 5.11.2. Trends in Application (2021-2030) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Facial Implants Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Sacral Nerve Stimulator 7.3.1. Sacral Nerve Stimulator market, 2021 - 2030 (USD Million) 7.4. Deep Brain Stimulator 7.4.1. Deep Brain Stimulator market, 2021 - 2030 (USD Million) 7.5. Gastric Electric Stimulator 7.5.1. Gastric Electric Stimulator market, 2021 - 2030 (USD Million) 7.6. Vagus Nerve Stimulator 7.6.1. Vagus Nerve Stimulator market, 2021 - 2030 (USD Million) 7.7. Spinal Cord Stimulator 7.7.1. Spinal Cord Stimulator market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Dystonia 8.3.1. Dystonia market, 2021 - 2030 (USD Million) 8.4. Depression 8.4.1. Depression market, 2021 - 2030 (USD Million) 8.5. Essential Tremor 8.5.1. Essential Tremor market, 2021 - 2030 (USD Million) 8.6. Urinary and Fecal Incontinence 8.6.1. Urinary and Fecal Incontinence market, 2021 - 2030 (USD Million) 8.7. Epilepsy 8.7.1. Epilepsy market, 2021 - 2030 (USD Million) 8.8. Pain Management 8.8.1. Pain Management market, 2021 - 2030 (USD Million) 8.9. Gastroparesis 8.9.1. Gastroparesis market, 2021 - 2030 (USD Million) 8.10. Parkinson’s Disease 8.10.1. Parkinson’s Disease market, 2021 - 2030 (USD Million) 8.11. Other 8.11.1. Other market, 2021 - 2030 (USD Million) 9. Market: Regional Outlook 9.1 North America 9.1.1. North America Market, By Product, 2021 - 2030 (USD Million) 9.1.4. North America Market, By Application, 2021 - 2030 (USD Million) 9.1.5. North America Market, by Country, 2021 - 2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. Market, By Product, 2021 - 2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada Market, By Product, 2021 - 2030 (USD Million) 9.1.4.2.2. Canada Market, By Region, 2021 - 2030 (USD Million) 9.1.4.2.3. Canada Market, By Applications, 2021 - 2030 (USD Million) 9.2. Europe 9.2.1. Europe Market, By Product, 2021 - 2030 (USD Million) 9.2.2. Europe Market, By Application, 2021 - 2030 (USD Million) 9.2.5. Europe Market, by country, 2021 - 2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. Market, By Product, 2021 - 2030 (USD Million) 9.2.4.1.2. U.K. Market, By Applications, 2021 - 2030 (USD Million) 9.2.4.1.3. U.K. Market, by region, 2021 - 2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany Market, By Product, 2021 - 2030 (USD Million) 9.2.4.2.2. Germany Market, By Application, 2021 - 2030 (USD Million) 9.2.4.2.3. Germany Market, by Region, 2021 - 2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France Market, By Product, 2021 - 2030 (USD Million) 9.2.4.3.2. France Market, By Region, 2021 - 2030 (USD Million) 9.2.4.3.3. France Market, By Application, 2021 - 2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe Market, By Product, 2021 - 2030 (USD Million) 9.2.4.4.2. Rest of Europe Market, By Region, 2021 - 2030 (USD Million) 9.2.4.4.3. Rest of Europe Market, By Application, 2021 - 2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific Market, By Product, 2021 - 2030 (USD Million) 9.3.2. Asia Pacific Market, By Application, 2021 - 2030 (USD Million) 9.3.5. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China Market, By Product, 2021 - 2030 (USD Million) 9.3.4.1.2. China Market, By Region, 2021 - 2030 (USD Million) 9.3.4.1.3. China Market, By Application, 2021 - 2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India Market, By Product, 2021 - 2030 (USD Million) 9.3.4.2.2. India Market, By Region, 2021 - 2030 (USD Million) 9.3.4.2.3. India Market, By Application, 2021 - 2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan Market, By Product, 2021 - 2030 (USD Million) 9.3.4.3.3. Japan Market, By Application, 2021 - 2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea Market, By Product, 2021 - 2030 (USD Million) 9.3.4.4.3. South Korea Market, By Application, 2021 - 2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC Market, By Product, 2021 - 2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC Market, By Application, 2021 - 2030 (USD Million) 9.4. Latin America 9.4.1. Latin America Market, By Product, 2021 - 2030 (USD Million) 9.4.3. Latin America Market, By Application, 2021 - 2030 (USD Million) 9.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil Market, By Product, 2021 - 2030 (USD Million) 9.4.4.1.3. Brazil Market, By Application, 2021 - 2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico Market, By Product, 2021 - 2030 (USD Million) 9.4.4.2.3. Mexico Market, By Application, 2021 - 2030 (USD Million) 9.4.4.3. Rest of the Latin America 9.4.4.3.1. Rest of the Latin American market, By Product, 2021 - 2030 (USD Million) 9.4.4.3.3. Rest of the Latin American market, By Application, 2021 - 2030 (USD Million) 9.5. MEA 9.5.1. MEA Market, By Product, 2021 - 2030 (USD Million) 9.5.3. MEA Market, By Application, 2021 - 2030 (USD Million) 10. Competitive Landscape 10.1 Medtronic. 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. Product Portfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. Boston Scientific Corporation. 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Abbott Laboratories. 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. LIVANOVA 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Synapse Biomedical. 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Nevro Corporation. 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. NeuroSigma, Inc 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. NeuroPace, Inc. 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. Neuronetics, Inc 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. BioControl Medical 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. Bioness 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development 10.12. Soterix Medical 10.12.1. Company overview 10.12.2. Financial performance 10.12.3. Product Portfolio Analysis 10.12.4. Business Strategy & Recent Development 10.13. Integer Holdings Corporation 10.13.1. Company overview 10.13.2. Financial performance 10.13.3. Product Portfolio Analysis 10.13.4. Business Strategy & Recent Development 10.14. Bioinduction 10.14.1. Company overview 10.14.2. Financial performance 10.14.3. Product Portfolio Analysis 10.14.4. Business Strategy & Recent Development 10.15. GiMer Medical 10.15.1. Company overview 10.15.2. Financial performance 10.15.3. Product Portfolio Analysis 10.15.4. Business Strategy & Recent Development 10.16. GTX Medical 10.16.1. Company overview 10.16.2. Financial performance 10.16.3. Product Portfolio Analysis 10.16.4. Business Strategy & Recent Development 10.17. Helius Medical Technologies 10.17.1. Company overview 10.17.2. Financial performance 10.17.3. Product Portfolio Analysis 10.17.4. Business Strategy & Recent Development 10.18. MicroTransponder 10.18.1. Company overview 10.18.2. Financial performance 10.18.3. Product Portfolio Analysis 10.18.4. Business Strategy & Recent Development 10.19. Neuronano 10.19.1. Company overview 10.19.2. Financial performance 10.19.3. Product Portfolio Analysis 10.19.4. Business Strategy & Recent Development 10.20. BlueWind 10.20.1. Company overview 10.20.2. Financial performance 10.20.3. Product Portfolio Analysis 10.20.4. Business Strategy & Recent Development List of Tables (70 Tables) TABLE 1. Market, By Product, 2021-2030 (USD Million) TABLE 2. Market FOR Sacral Nerve Stimulator, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Deep Brain Stimulator, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Gastric Electric Stimulator, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Vagus Nerve Stimulator, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Spinal Cord Stimulator, BY REGION, 2021-2030 (USD Million) TABLE 7. Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 8. Market FOR Dystonia, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Depression, BY REGION, 2021-2030 (USD Million) TABLE 10. Market FOR Essential Tremor, BY REGION, 2021-2030 (USD Million) TABLE 11. Market FOR Urinary and Fecal Incontinence, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Epilepsy, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Pain Management, BY REGION, 2021-2030 (USD Million) TABLE 14. Market FOR Gastroparesis, BY REGION, 2021-2030 (USD Million) TABLE 15. Market FOR Parkinson’s Disease, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Other, BY REGION, 2021-2030 (USD Million) TABLE 17. Market, BY REGION, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA Market, By Applications, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, By Product, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 22. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 23. EUROPE Market, By Product, 2021-2030 (USD Million) TABLE 24. EUROPE Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 25. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC Market, By Product, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 28. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 29. LAMEA Market, By Product, 2021-2030 (USD Million) TABLE 30. LAMEA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. Medtronic: COMPANY SNAPSHOT TABLE 32. Medtronic: OPERATING SEGMENTS TABLE 33. Boston Scientific Corporation: COMPANY SNAPSHOT TABLE 34. Boston Scientific Corporation: OPERATING SEGMENTS TABLE 35. Abbott Laboratories: COMPANY SNAPSHOT TABLE 36. Abbott Laboratories: OPERATING SEGMENTS TABLE 37. LIVANOVA: COMPANY SNAPSHOT TABLE 38. LIVANOVA: OPERATING SEGMENTS TABLE 39. Synapse Biomedical.: COMPANY SNAPSHOT TABLE 40. Synapse Biomedical.: OPERATING SEGMENTS TABLE 41. Nevro Corporation: COMPANY SNAPSHOT TABLE 42. Nevro Corporation: OPERATING SEGMENTS TABLE 43. NeuroSigma, Inc: COMPANY SNAPSHOT TABLE 44. NeuroSigma, Inc: OPERATING SEGMENTS TABLE 45. NeuroPace, Inc: COMPANY SNAPSHOT TABLE 46. NeuroPace, Inc: OPERATING SEGMENTS TABLE 47. Neuronetics, Inc: COMPANY SNAPSHOT TABLE 48. Neuronetics, Inc: OPERATING SEGMENTS TABLE 49. BioControl Medical: COMPANY SNAPSHOT TABLE 50. BioControl Medical: OPERATING SEGMENTS TABLE 51. Bioness: COMPANY SNAPSHOT TABLE 52. Bioness: OPERATING SEGMENTS TABLE 53. Soterix Medical: COMPANY SNAPSHOT TABLE 54. Soterix Medical: OPERATING SEGMENTS TABLE 55. Integer Holdings Corporation: COMPANY SNAPSHOT TABLE 56. Integer Holdings Corporation: OPERATING SEGMENTS TABLE 57. Bioinduction: COMPANY SNAPSHOT TABLE 58. Bioinduction: OPERATING SEGMENTS TABLE 59. GiMer Medical: COMPANY SNAPSHOT TABLE 60. GiMer Medical: OPERATING SEGMENTS TABLE 61. GTX Medical: COMPANY SNAPSHOT TABLE 62. GTX Medical: OPERATING SEGMENTS TABLE 63. Helius Medical Technologies: COMPANY SNAPSHOT TABLE 64. Helius Medical Technologies: OPERATING SEGMENTS TABLE 65. MicroTransponder: COMPANY SNAPSHOT TABLE 66. MicroTransponder: OPERATING SEGMENTS TABLE 67. Neuronano: COMPANY SNAPSHOT TABLE 68. Neuronano: OPERATING SEGMENTS TABLE 69. BlueWind: COMPANY SNAPSHOT TABLE 70. BlueWind: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 20 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Neuromodulation Devices, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Neuromodulation Devices, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11Market, By Applications, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Product, 2019 vs. 2025 Figure 13 Geographical Snapshot of the Market Figure 14 Spinal Cord Stimulator to Witness Higher CAGR in the Market for Product Segment During the Forecast Period. Figure 15 Pain Management to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 17Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Market Snapshot Figure 19 Asia Pacific: Market Snapshot Figure 20 Vendor Dive: Evaluation Overview